Pfizer CFO Dave Denton to Step Down in August
Interim Chief Financial Officer Cecile Guegan takes over as Pfizer launches search for permanent replacement.
By the FiledFeed automated desk
This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.
The short version
Dave Denton, Pfizer's Chief Financial Officer, will step down on August 15 to pursue an opportunity in consumer goods outside the pharmaceutical industry. Cecile Guegan, currently Senior Vice President of Finance for Pfizer's Global Biopharmaceutical Business, will become Interim Chief Financial Officer effective August 16 while the company searches for a permanent successor.
Filing impact
Filing sentiment
Pfizer Inc. announced that Dave Denton, its Chief Financial Officer, will leave the company on August 15 to take a job in the consumer goods industry outside pharmaceuticals.
Cecile Guegan, who currently serves as Senior Vice President of Finance for Pfizer's Global Biopharmaceutical Business, has been named Interim Chief Financial Officer, starting August 16. She will lead the finance organization while Pfizer conducts both internal and external searches for a permanent replacement.
In a statement, Chief Executive Officer Albert Bourla praised Denton's tenure, highlighting his role in major business deals including the company's acquisitions of Seagen, Biohaven, and Metsera. Bourla expressed confidence in Guegan's ability to lead, noting her "deep institutional knowledge and financial acumen." Denton and Guegan are expected to work together to ensure a smooth handoff during the transition period.
Guegan brings more than 20 years of experience at Pfizer. In her current role, she manages the financial operations and reporting of Pfizer's biopharmaceutical business across all therapy types and regions. She has a track record of leading major company-wide initiatives, including the integration of Seagen, which Pfizer acquired in 2024. She holds a Master in Business degree from Brest Business School.
Why it matters
Executive turnover in the CFO role can affect investor confidence in financial oversight and continuity of strategy execution, especially at a large pharmaceutical company overseeing major acquisitions and complex financial operations. While Denton's departure appears planned and voluntary, the interim appointment of an internal candidate signals Pfizer's intention to maintain operational stability. Guegan's deep familiarity with the company and recent track record on major deals (Seagen integration) may reduce short-term transition risk. The search for a permanent CFO will be closely watched by investors as an indicator of the company's leadership bench strength and strategic direction.
Frequently asked
- Why is Dave Denton stepping down as Pfizer's CFO?
- Denton is leaving on August 15, 2026, to pursue a professional opportunity in the consumer goods industry outside of pharmaceuticals.
- Who is replacing Dave Denton as CFO?
- Cecile Guegan, currently Senior Vice President of Finance for Pfizer's Global Biopharmaceutical Business, has been named Interim Chief Financial Officer, effective August 16, 2026. Pfizer is conducting an internal and external search for a permanent replacement.
- What is Cecile Guegan's background at Pfizer?
- Guegan has more than 20 years of experience at Pfizer. She currently oversees financial operations and reporting for the biopharmaceutical business across all therapeutic areas and regions. She led the integration of Seagen into Pfizer in 2024.
- What will happen during the transition between the two CFOs?
- Denton and Guegan will work together between August 15 and August 16 to ensure a seamless transition of the CFO role.
What the filing reported
- 5.02 Departure/Election of Directors or Officers
- 9.01 Financial Statements & Exhibits
Source
Based on PFIZER INC's 8-K filed with the SEC on Jun 18, 2026. Read the original filing on SEC.gov ↗